[1] Margolin E, Freund P. Third nerve palsies:review[J]. Int Ophthalmol Clin, 2019, 59:99-112.
[2] Fang CB, Leavitt JA, Hodge DO, Holmes JM, Mohney BG, Chen JJ. Incidence and etiologies of acquired third nerve palsy using a population-based method[J]. JAMA Ophthalmol, 2017, 135:23-28.
[3] Keane JR. Third nerve palsy:analysis of 1400 personally-examined inpatients[J]. Can J Neurol Sci, 2010, 37:662-670.
[4] Fu J, Peng LL, Liu YG, Li JL, He XY, Li XG. Etiology analysis of 23 cases of oculomotor nerve palsy[J]. Hainan Yi Xue, 2016, 27:2365-2367.[付洁, 彭里磊, 刘永刚, 李经伦, 何晓英, 李小刚. 动眼神经麻痹23例病因分析[J]. 海南医学, 2016, 27:2365-2367.]
[5] Wang R, Zhang QM, Wang D, Yuan J. Clinical features and prognosis of oculomotor nerve palsy[J]. Zhongguo Shi Yong Shen Jing Ji Bing Za Zhi, 2016,19:93-94.[汪锐, 张启明, 王丹, 袁菁. 动眼神经麻痹的临床特点及预后分析[J]. 中国实用神经疾病杂志, 2016, 19:93-94.]
[6] Galtrey CM, Schon F, Nitkunan A. Microvascular non-arteritic ocular motor nerve palsies:what we know and how should we treat[J]? Neuroophthalmology, 2014, 39:1-11.
[7] Weber RB, Daroff RB, MacKey EA. Pathology of oculomotor nerve palsy in diabetics[J]. Neurology, 1970, 20:835-838.
[8] Gluckstein J, Prasad S. Infectious ocular motor neuropathies[J]. Curr Opin Ophthalmol, 2019, 30:454-461.
[9] Jung JS, Kim DH. Risk factors and prognosis of isolated ischemic third, fourth, or sixth cranial nerve palsies in the Korean population[J]. J Neuroophthalmol, 2015, 35:37-40.
[10] Tamhankar MA, Biousse V, Ying GS, Prasad S, Subramanian PS, Lee MS, Eggenberger E, Moss HE, Pineles S, Bennett J,Osborne B, Volpe NJ, Liu GT, Bruce BB, Newman NJ, Galetta SL, Balcer LJ. Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes:a prospective study[J]. Ophthalmology, 2013, 120:2264-2269.
[11] Dhume KU, Paul KE. Incidence of pupillary involvement, course of anisocoria and ophthalmoplegia in diabetic oculomotor nerve palsy[J]. Indian J Ophthalmol, 2013, 61:13-17.
[12] Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, James P, Kyle V, Nott J, Power M, Samanta A; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis[J]. Rheumatology (Oxford), 2010, 49:1594-1597.
[13] Lin XM, Song JX, Wang F, Wang J, Lu QL, Wu SD. Analysis of the etiologies and clinical features of 56 patients with oculomotor nerve palsy[J]. Diao Cha Fen Xi, 2019, 30:13-17.[蔺雪梅, 宋金鑫, 王芳, 王静, 逯青丽, 吴松笛. 56例动眼神经麻痹患者的病因及临床特点分析[J]. 调查分析, 2019, 30:13-17.]
[14] Orz Y, Al Yamany M. The impact of size and location on rupture of intracranial aneurysms[J]. Asian J Neurosurg, 2015, 10:26-31.
[15] Vaphiades MS, Roberson GH. Imaging of oculomotor (third) cranial nerve palsy[J]. Neurol Clin, 2017, 35:101-113.
[16] Elmalem VI, Hudgins PA, Bruce BB, Newman NJ, Biousse V. Underdiagnosis of posterior communicating artery aneurysm in noninvasive brain vascular studies[J]. J Neuroophthalmol, 2011, 31:103-109.
[17] Trobe JD. Third nerve palsy and the pupil:footnotes to the rule[J]. Arch Ophthalmol, 1988, 106:601-602.
[18] Newman NJ, Biousse V. Third nerve palsies:less frequent but just as concerning[J]. JAMA Ophthalmol, 2017, 135:29-30.
[19] Ogawa K, Suzuki Y, Takahashi K, Kamei S, Ishikawa H. Clinical study of eleven patients with midbrain infarction-induced oculomotor nerve palsy[J]. J Stroke Cerebrovasc Dis, 2016, 25:1631-1638.
[20] Johnson LN, Stetson SW, Krohel GB, Cipollo CL, Madsen RW. Aspirin use and the prevention of acute ischemic cranial nerve palsy[J]. Am J Ophthalmol, 2000, 129:367-371.
[21] Kung NH, van Stavern GP. Isolated ocular motor nerve palsies[J]. Semin Neurol, 2015, 35:539-548. |